S&P Futures
3,940.50 -6.50 (-0.16%) Dow Futures
31,993.00 -78.00 (-0.24%) Nasdaq Futures
12,641.75 -3.00 (-0.02%) Russell 2000 Futures
1,738.10 -0.30 (-0.02%) Crude Oil
64.63 -2.11 (-3.16%) Gold
1,992.90 +19.40 (+0.98%)
Cellectis SA (ZVA.MU)
Chart Events
Performance Outlook
| Previous Close | 1.8510 |
| Open | 1.8510 |
| Bid | 1.7460 x 0 |
| Ask | 1.7920 x 0 |
| Day's Range | 1.8510 - 1.8510 |
| 52 Week Range | 1.8510 - 4.5500 |
| Volume | |
| Avg. Volume | 14 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ZVA.MU
Related Research
- GlobeNewswire
Monthly information on share capital and company voting rights
(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights02/28/202355,583,76861,651,088 About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunothe
- GlobeNewswire
Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting
NEW YORK, March 14, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preclinical data exploring purposeful armoring of CAR T-cells to enhance efficacy of MUC1 CAR T-cells in targeting triple-negative breast cancer, will be presented at the American Association of Cancer Research (AACR) Annual Meeting, to
- GlobeNewswire
Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented in a Live Webcast; First patient dosed with UCART22 product candidate fully manufactured in-house Encouraging preliminary results from Phase 1 AMELI-01 study
